What went wrong in Connect Biopharma’s Seabreeze STAT asthma trial?
CNTB falls 32% after rademikibart misses its asthma primary endpoint despite a 66% treatment-failure reduction and significant FEV1 gain.
Pharma & Biotech
Pharma & Biotech
Why Bambusa Therapeutics’ BBT001 data are drawing attention in atopic dermatitis beyond a routine Phase 1 update
Bambusa Therapeutics’ BBT001 showed strong Phase 1 activity in atopic dermatitis. Read what it could change and what risks remain.